EMBI - Emerald Bioscience Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2190
-0.0010 (-0.45%)
As of 10:16AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.2200
Open0.2191
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2100 - 0.2200
52 Week Range0.2050 - 1.1700
Volume115,146
Avg. Volume168,393
Market Cap29.367M
Beta (3Y Monthly)0.24
PE Ratio (TTM)N/A
EPS (TTM)-0.0900
Earnings DateAug 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.48
  • GlobeNewswire

    Emerald Bioscience Announces $2.0 Million Registered Direct Offering

    This press release shall not constitute an offer to sell, or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Emerald Bioscience is a biopharmaceutical company headquartered in Long Beach, California, focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets. With proprietary technology licensed from the University of Mississippi, Emerald is developing novel ways to deliver cannabinoid-based drugs for specific indications with the aim of optimizing the clinical effects of such drugs while limiting potential adverse events.

  • GlobeNewswire

    Emerald Bioscience to Present at Cowen 2nd Annual Boston Cannabis Conference

    LONG BEACH, CA, Nov. 04, 2019 -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications,.

  • GlobeNewswire

    Emerald Bioscience to Present Research Data Related to its Glaucoma Drug Candidate, NB1111, at 2019 American Association of Pharmaceutical Scientists

    Long Beach, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced that the University of Mississippi and Eli Labs will present preclinical data evaluating the superiority of its prodrug of tetrahydrocannabinol (THC), NB1111, in lowering intraocular pressure in a multi-dose normotensive rabbit model when compared to the current standards of care in glaucoma treatment, timolol and latanoprost, at the 2019 American Association of Pharmaceutical Scientists Meeting (AAPS) being held November 3 -6, 2019, at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

  • GlobeNewswire

    Emerald Bioscience’s NB1111 Demonstrates Superiority in Lowering Intraocular Pressure Compared to Global Standard of Care Glaucoma Treatment in Preclinical Model

    Increased IOP is a cause of glaucoma, and in this study NB1111 was compared to the current IOP-lowering standards-of-care for treating glaucoma: latanoprost, a prostaglandin-based therapy, and timolol, a beta-blocker. In this study, intraocular pressure (IOP) was measured in normotensive (normal ocular pressure) rabbits following a single topical dose of Bioscience’s proprietary nanoemulsion formulation of NB1111 compared to commercially available formulations of latanoprost and timolol.

  • GlobeNewswire

    Glauconix Presents Data Validating Impact of Emerald Bioscience’s Prodrug on the Ocular Endocannabinoid System in Glaucoma

    The data demonstrated THC’s ability to lower intraocular pressure in the eye by enhancing drainage of ocular fluid over the trabecular meshwork, one of the major tissues for regulating IOP in the eye. The meshwork is known to contain a high density of cannabinoid receptors, a binding target of THC, indicating NB1111’s potential as a promising drug candidate to treat glaucoma and possibly other ocular disorders that threaten the optic nerve.  In addition, THC also lowered biomarkers associated with inflammation and fibrosis, two processes associated with damaged tissues, indicating a previously unrecognized interaction between the endocannabinoid system and the inflammatory cascade in the eye.

  • GlobeNewswire

    Glauconix Biosciences and University of Mississippi to Present Research Data Related to Emerald Bioscience’s Glaucoma Drug Candidate, NB1111, at 2019 American Academy of Ophthalmology Annual Meeting

    Long Beach, Calif., Oct. 03, 2019 -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global.

  • GlobeNewswire

    Emerald Bioscience to Participate in Investment and Scientific Conferences in September

    Long Beach, Calif., Aug. 27, 2019 -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global.

  • GlobeNewswire

    Emerald Bioscience Appoints Chief Medical Officer and Executive Director, Clinical Operations

    Long Beach, CA, Aug. 26, 2019 -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global.

  • GlobeNewswire

    Emerald Bioscience Starts Australian Operation Ahead of Planned Glaucoma Study

    Long Beach, Calif., Aug. 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, announced today that the company has opened its Australian office. The formation of EMBI Australia Pty Ltd and opening of an Australian office is an important step in meeting regulatory requirements to conduct studies in Australia and represents EMBI’s commitment to initiate its first-in-human study of NB1111, the prodrug of THC, in the indication of glaucoma.

  • GlobeNewswire

    Emerald Bioscience to Participate in 29th Annual International Cannabinoid Research Symposium (ICRS)

    Long Beach, Calif., June 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, announced today that two posters related to its glaucoma therapeutic candidate, NB1111, will be presented at the 29th Annual Symposium of the International Cannabinoid Research Society. “Emerald Bioscience continues to focus on meeting milestones in the development of cannabinoids to treat diseases of the eye.

  • GlobeNewswire

    Emerald Bioscience’s NB2222 Exhibits Superior Ocular Permeation into Multiple Compartments of the Eye Compared to Cannabidiol

    LONG BEACH, CA, June 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (EMBI), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, today announced that newly published scientific data highlight the superior penetration of EMBI’s drug candidate, NB2222, into ocular tissues in comparison to natural cannabidiol (CBD). Published studies have demonstrated that cannabinoids interrupt the apoptosis or programmed cell death cycle in damaged retinal ganglion cells, leading to greater survival of nerve tissue that supply vision. Cannabidiol (CBD) has known anti-inflammatory properties that could potentially help treat traumatic, infectious, and retinopathy-associated pain and inflammation.

  • GlobeNewswire

    Emerald Bioscience to Present at the 9th Annual LD Micro Invitational

    LONG BEACH, CA, June 03, 2019 -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on bioengineered cannabinoid-based.

  • GlobeNewswire

    Emerald Bioscience Secures “All Fields” Licenses for Cannabinoid Derivatives Developed by University of Mississippi

    LONG BEACH, CA, May 29, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (EMBI), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, has signed licenses covering “all fields of use” pertaining to proprietary cannabinoid- derivative molecules developed by the University of Mississippi (UM), including a prodrug of tetrahydrocannabinol (THCVHS) and analog of cannabidiol (CBDVHS) being developed to treat ocular diseases.

  • PR Newswire

    Cannastocks2019 Investor Conference & Webinar Now Available for On-Demand Viewing

    Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations NEW YORK , May 17, 2019 /PRNewswire/ -- Virtual Investor Conferences, ...

  • CNW Group

    Cannastocks2019 Live-Stream Investor Conference & Webinar May 15th

    Cannastocks2019 Live-Stream Investor Conference & Webinar May 15th

  • GlobeNewswire

    Emerald Bioscience to Participate at the CannaStocks 2019 Q1 Investor Conference

    LONG BEACH, CA , May 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, announced today that Dr. Brian Murphy, CEO and Chief Medical Officer, will present at the CannaStocks 2019 Q1 Investor Conference on Wednesday, May 15, 2019 at 11 AM EDT  at the OTC Markets Group Headquarters, 300 Vesey Street, New York, NY. For those investors unable to attend in person, a live streaming video webcast of the event will be available on the Virtual Investor Conferences.

  • Benzinga

    'Beyond CBD': Emerald Health Bioceuticals' CEO On The Company's Endocannabinoid Health Products Line

    Emerald Bioscience Inc (OTC: EMBI), a company that’s part of the Emerald Health Sciences portfolio, has more than doubled in value since the beginning of the year. Emerald Health Bioceuticals is a company focusing on phytocannabinoid science. The company’s “Beyond CBD” line aims to offer a comprehensive and yet condition-specific approach to endocannabinoid health without the stigma, legality or drug testing concerns associated with hemp and cannabis.

  • GlobeNewswire

    Emerald Bioscience Announces Ophthalmology Scientific Advisory Board Members

    Long Beach, CA, April 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (EMBI), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, today announced members of the company’s Ophthalmology Scientific Advisory Board (OSAB). The purpose of the OSAB is to provide scientific and clinical guidance relating to EMBI’s proprietary cannabinoid-based drug platform to address diseases of the eye. “Emerald Bioscience is leading the development of cannabinoid-based therapeutics to address diseases of the eye.

  • GlobeNewswire

    Emerald Bioscience to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

    LONG BEACH, CA, April 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based therapeutics to address global medical indications, today announced that CEO and Chief Medical Officer Dr. Brian Murphy will present a corporate overview at the upcoming H.C. Wainwright Global Life Sciences Conference taking place at the Grosvenor House  in London, UK. Emerald Bioscience is a biopharmaceutical company headquartered in Long Beach, California, focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets.

  • GlobeNewswire

    Emerald Bioscience, Inc. Announces DEA Decision that its Proprietary Cannabidiol Analog is not a Regulated Chemical or Controlled Substance Under Controlled Substances Act

    LONG BEACH, CA, April 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based therapeutics to address global medical indications, today announced that the Drug Enforcement Administration (DEA) has conducted a scientific review of the chemical structure of cannabidiol-­valine-hemisuccinate (CBDVHS) and determined that CBDVHS is not a regulated chemical nor controlled substance under the Controlled Substances Act. Emerald Bioscience is a biopharmaceutical company headquartered in Long Beach, California, focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets.